Format
Sealed research vial
Trust signal
COA-backed inventory
Safety Data Sheet
Download SDS
Full safety documentation for this compound.
99%+ Purity
Lab-grade supply. Limited AU stock.
From A$144.99
Select options below
Size
Select one
Select your preferred options to continue.
Third-party tested · 99%+ purity · Dispatched within 24h from Melbourne · 4.8★ #1 on Trustpilot
Fast AU dispatch, tracked delivery, and documentation-ready inventory.
Multi-buy: any 3+ items, 15% off everything — applied automatically.
Why labs buy from APL
High purity, consistent supply, and fast AU-wide dispatch.
Certificate of Analysis
Certificate of Analysis
Verified purity: 99.554%
Retatrutide
From A$144.99
Retatrutide is a 36-amino acid GLP-1R/GIPR/GcgR triple agonist representing the first published peptide with balanced full agonism across all three incretin/glucagon-axis receptors.
The key research design challenge is separating the individual receptor contributions in cell systems that co-express some or all three targets. Selective antagonists or receptor-knockout models used alongside retatrutide enable attribution of specific readouts to each pathway, making comparator design more demanding but more informative than single-pathway assays.
Browse Inventory
In research literature, Retatrutide is generally treated as a 36-amino acid GLP-1R/GIPR/GcgR triple agonist representing the first published peptide with balanced full agonism across all three incretin/glucagon-axis receptors. Retatrutide activates GLP-1R and GIPR via the same Gs-cAMP-PKA cascade as tirzepatide, while also engaging the glucagon receptor (GcgR), which adds pathway outputs relevant to hepatic glucose production and fatty acid oxidation assay models. Achieving balanced potency across three structurally similar class B GPCRs simultaneously required extensive sequence engineering — studies examining its binding mode at each receptor provide a useful platform for understanding receptor-selectivity determinants within the incretin peptide family.
The key research design challenge is separating the individual receptor contributions in cell systems that co-express some or all three targets. Selective antagonists or receptor-knockout models used alongside retatrutide enable attribution of specific readouts to each pathway, making comparator design more demanding but more informative than single-pathway assays. For laboratory teams, the practical emphasis is usually on sequence identity, receptor or pathway relevance where documented, and whether Retatrutide behaves consistently across stability, purity, and analytical verification workflows. Variant labels on this page support clearer internal referencing when multiple labelled variants are under review.
Potential research applications for Retatrutide should be framed strictly in analytical and laboratory terms. Typical reasons a team might review this product page include:
Handling decisions should always follow the vial label, internal SOPs, and any product-specific documentation. A conservative laboratory baseline for Retatrutide is:
A product-specific COA is linked on this page, with purity noted as 99.554%. The COA section is useful for confirming how the product is labelled in the catalogue, whether purity information has been published, and whether the laboratory record for the material is complete before bench use.
When teams compare Retatrutide with NAD+, PT-141, and Tesamorelin, COA access also helps keep comparator decisions grounded in documented material identity rather than assumption. That is especially important for research pages that combine pricing, variant selection, and analytical records on a single URL.
Certificate of Analysis
Certificate of Analysis
Verified purity: 99.554%
It brings together 5 labelled variants: 15mg, 10mg, 30mg, 20mg, and 40mg, current pricing context, stock visibility, COA access, and internal links to related catalogue pages so a laboratory buyer can review the material from a single reference URL.
Retatrutide is generally discussed as a 36-amino acid GLP-1R/GIPR/GcgR triple agonist representing the first published peptide with balanced full agonism across all three incretin/glucagon-axis receptors. The most relevant background is sequence behaviour, pathway or receptor context where documented, and analytical consistency under controlled laboratory conditions.
Use the label, COA, and internal SOPs as the primary guide. In general, store the material under controlled laboratory conditions, minimise avoidable environmental exposure, and keep variant tracking records current.
Yes. This listing includes access to a product-specific COA, which should be reviewed before use so purity, identity, and documentation checks are aligned with the project record.
No. The page should be interpreted strictly in a research and laboratory context. It does not provide dosage guidance, treatment claims, or human or animal use instructions.
